Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895908498> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2895908498 abstract "Crenezumab is an investigational anti-Aβ antibody intended to predominantly target Aβ oligomers (AβO) and is currently in development for prodromal-to-mild Alzheimer's disease. We used an ultrasensitive in-house immunoassay to measure AβO levels in CSF from AD subjects before and after treatment with crenezumab vs. placebo. CSF samples at baseline and week 69 were available from 104 subjects from the ABBY (Cummings 2018) and BLAZE Phase 2 trials. Patients received subcutaneous (SC) crenezumab (300mg) or placebo every two weeks, or else intravenous (IV) crenezumab (15mg/kg) or placebo every four weeks, for 68 weeks. AβO levels were measured using an optimized Erenna-based immunoassay employing the aggregate-preferring mAb, 1C22, for capture, and 3D6 for detection (Yang 2015). Operators were blinded to sample identity. To minimize variance arising from plate-to-plate and day-to-day differences, baseline and 69 week samples from the same patient were measured in neighboring wells of the same plate. Paired CSF samples were analyzed from placebo (N=31), SC (N=36) and IV (N=37) treated patients from both BLAZE and ABBY. Of 104 paired samples analyzed, 98 had baseline CSF AβO values above the lower limit of quantification (LLoQ). In those 98 patients, treatment with crenezumab was associated with a consistent decrease in AβO levels. Specifically, 86% of IV and 89% of SC patients had lower levels of AβO at week 69 than at baseline. The median percentage change was -42% in the IV arm and -48% in the SC arm, with 21% and 13% of patients falling below the LLoQ after treatment. In contrast, no systematic change was observed in the placebo group, with a median change of -13% and equivalent portions with negative and positive change (54% of the placebo patients had lower AβO levels at week 69). The difference in proportions of patients with decreasing levels was significant for both treatment arms: p=0.001 for SC, and p=0.01 for IV crenezumab vs. placebo. Crenezumab lowers AβO levels in CSF in the large majority of tested patients. These results strongly suggest engagement of the principal target and recommend assaying CSF AβO in future trials of anti-Aβ agents . Crenezumab treatment lowers CSF Abeta oligomer levels. Boxplots of the AbetaO levels at baseline and week 69. Dots represent mean levels of individual patient. Samples yielding values below the LLoQ are shown in red. Boxes = 25-75 percentile; horizontal bar = median." @default.
- W2895908498 created "2018-10-26" @default.
- W2895908498 creator A5005477431 @default.
- W2895908498 creator A5006688727 @default.
- W2895908498 creator A5010115566 @default.
- W2895908498 creator A5011731306 @default.
- W2895908498 creator A5029105145 @default.
- W2895908498 creator A5058760107 @default.
- W2895908498 creator A5066081723 @default.
- W2895908498 creator A5071760235 @default.
- W2895908498 creator A5087935119 @default.
- W2895908498 date "2018-07-01" @default.
- W2895908498 modified "2023-10-16" @default.
- W2895908498 title "DT‐02‐03: TARGET ENGAGEMENT IN AN AD TRIAL: CRENEZUMAB LOWERS Aβ OLIGOMER LEVELS IN CSF" @default.
- W2895908498 doi "https://doi.org/10.1016/j.jalz.2018.07.012" @default.
- W2895908498 hasPublicationYear "2018" @default.
- W2895908498 type Work @default.
- W2895908498 sameAs 2895908498 @default.
- W2895908498 citedByCount "3" @default.
- W2895908498 countsByYear W28959084982019 @default.
- W2895908498 countsByYear W28959084982020 @default.
- W2895908498 crossrefType "journal-article" @default.
- W2895908498 hasAuthorship W2895908498A5005477431 @default.
- W2895908498 hasAuthorship W2895908498A5006688727 @default.
- W2895908498 hasAuthorship W2895908498A5010115566 @default.
- W2895908498 hasAuthorship W2895908498A5011731306 @default.
- W2895908498 hasAuthorship W2895908498A5029105145 @default.
- W2895908498 hasAuthorship W2895908498A5058760107 @default.
- W2895908498 hasAuthorship W2895908498A5066081723 @default.
- W2895908498 hasAuthorship W2895908498A5071760235 @default.
- W2895908498 hasAuthorship W2895908498A5087935119 @default.
- W2895908498 hasConcept C126322002 @default.
- W2895908498 hasConcept C126894567 @default.
- W2895908498 hasConcept C142724271 @default.
- W2895908498 hasConcept C159654299 @default.
- W2895908498 hasConcept C203014093 @default.
- W2895908498 hasConcept C204787440 @default.
- W2895908498 hasConcept C27081682 @default.
- W2895908498 hasConcept C2780420688 @default.
- W2895908498 hasConcept C535046627 @default.
- W2895908498 hasConcept C71924100 @default.
- W2895908498 hasConcept C90924648 @default.
- W2895908498 hasConcept C99476002 @default.
- W2895908498 hasConceptScore W2895908498C126322002 @default.
- W2895908498 hasConceptScore W2895908498C126894567 @default.
- W2895908498 hasConceptScore W2895908498C142724271 @default.
- W2895908498 hasConceptScore W2895908498C159654299 @default.
- W2895908498 hasConceptScore W2895908498C203014093 @default.
- W2895908498 hasConceptScore W2895908498C204787440 @default.
- W2895908498 hasConceptScore W2895908498C27081682 @default.
- W2895908498 hasConceptScore W2895908498C2780420688 @default.
- W2895908498 hasConceptScore W2895908498C535046627 @default.
- W2895908498 hasConceptScore W2895908498C71924100 @default.
- W2895908498 hasConceptScore W2895908498C90924648 @default.
- W2895908498 hasConceptScore W2895908498C99476002 @default.
- W2895908498 hasIssue "7S_Part_31" @default.
- W2895908498 hasLocation W28959084981 @default.
- W2895908498 hasOpenAccess W2895908498 @default.
- W2895908498 hasPrimaryLocation W28959084981 @default.
- W2895908498 hasRelatedWork W195854409 @default.
- W2895908498 hasRelatedWork W2009588589 @default.
- W2895908498 hasRelatedWork W2080033839 @default.
- W2895908498 hasRelatedWork W2107452578 @default.
- W2895908498 hasRelatedWork W2144684835 @default.
- W2895908498 hasRelatedWork W2392413698 @default.
- W2895908498 hasRelatedWork W2970916347 @default.
- W2895908498 hasRelatedWork W3015996685 @default.
- W2895908498 hasRelatedWork W4231318786 @default.
- W2895908498 hasRelatedWork W2118673085 @default.
- W2895908498 hasVolume "14" @default.
- W2895908498 isParatext "false" @default.
- W2895908498 isRetracted "false" @default.
- W2895908498 magId "2895908498" @default.
- W2895908498 workType "article" @default.